Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results from Bioenvision's ongoing phase II study of its developmental drug BIVN-401 for the treatment of chronic hepatitis C, show that the drug produces a significant reduction in viral load in most patients.
Subscribe to our email newsletter
BIVN-401 was given to 25 patients with genotype 4 hepatitis C who had failed a prior treatment. The drug was given orally for 100 days and measurement of the viral load was made at 50 days.
At 50 days, 22 (88%) patients had shown a reduction in viral load of greater than 70%. Of these responders, 14 (64%) had a clearance of greater than 90%, with 4 responders having complete viral clearance.
Seven of the 25 patients have had viral load measured at 100 days. Six of these patients show continued reduction in viral load and the seventh patient, who had been one of the three non-responders at 50 days, had a greater than 90% reduction in viral load.
“Virostat is a highly active anti-viral agent and we are delighted with the responses in this difficult to treat group of patients” said Dr Christopher Wood, CEO of Bioenvision.